# Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

> **NCT05035927** · PHASE2 · COMPLETED · sponsor: **TRYP Therapeutics** · enrollment: 5 (actual)

## Conditions studied

- Binge Eating Disorder

## Interventions

- **DRUG:** TRYP-0082
- **BEHAVIORAL:** Psychotherapy

## Key facts

- **NCT ID:** NCT05035927
- **Lead sponsor:** TRYP Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-03-16
- **Primary completion:** 2024-03-07
- **Final completion:** 2024-06-07
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2024-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05035927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05035927, "Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05035927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*